Allena Pharmaceuticals Inc (ALNA) Given Consensus Rating of “Hold” by Analysts

Allena Pharmaceuticals Inc (NASDAQ:ALNA) has been assigned a consensus rating of “Hold” from the six research firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $22.00.

ALNA has been the topic of a number of research reports. Wedbush initiated coverage on Allena Pharmaceuticals in a report on Monday, November 27th. They issued an “outperform” rating and a $30.00 price objective on the stock. Credit Suisse Group initiated coverage on Allena Pharmaceuticals in a report on Monday, November 27th. They issued an “outperform” rating and a $22.00 price objective on the stock. ValuEngine upgraded Allena Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Cowen initiated coverage on Allena Pharmaceuticals in a report on Monday, November 27th. They set an “outperform” rating on the stock. Finally, Jefferies Group initiated coverage on Allena Pharmaceuticals in a report on Monday, November 27th. They set a “buy” rating and a $22.00 price target on the stock.

A number of hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp acquired a new position in Allena Pharmaceuticals during the fourth quarter valued at approximately $102,000. Dean Capital Investments Management LLC acquired a new position in Allena Pharmaceuticals during the fourth quarter valued at approximately $116,000. BlackRock Inc. acquired a new position in Allena Pharmaceuticals during the fourth quarter valued at approximately $2,281,000. Finally, Sphera Funds Management LTD. acquired a new position in Allena Pharmaceuticals during the fourth quarter valued at approximately $3,270,000. Institutional investors own 0.07% of the company’s stock.

Allena Pharmaceuticals (NASDAQ:ALNA) traded down $0.25 during trading hours on Tuesday, reaching $6.30. The company had a trading volume of 46,144 shares, compared to its average volume of 53,568. Allena Pharmaceuticals has a 12-month low of $6.24 and a 12-month high of $15.40. The company has a debt-to-equity ratio of -0.09, a quick ratio of 4.83 and a current ratio of 4.83.

Allena Pharmaceuticals (NASDAQ:ALNA) last released its quarterly earnings data on Thursday, December 14th. The company reported ($3.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($3.11). sell-side analysts anticipate that Allena Pharmaceuticals will post -0.89 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Allena Pharmaceuticals Inc (ALNA) Given Consensus Rating of “Hold” by Analysts” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2018/02/13/allena-pharmaceuticals-inc-alna-given-consensus-rating-of-hold-by-analysts.html.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply